Ulcerative Colitis

Taha Qazi, MD, summarizes his research presented at ACG 2019 comparing objective sleep parameters in minority IBD patients compared to Caucasian IBD patients.

In a poster presented at the annual ACG meeting, investigators estimate the prevalence of medication use by drug class for IBD-patients based on age.

After 44 weeks of maintenance therapy, endoscopic improvement was observed in 43.6% and 51.1% of patients treated with the study drug q12w and q8w, respectively.

Among patients with UC, elderly individuals (age >65 years old), females, and Caucasians were more likely to be affected by psychiatric illness.

Compared to hospitalized patients with ulcerative colitis but without C diff infection, hospitalized patients with ulcerative colitis and C diff experienced increased mortality.

Investigators present data from a new study showing that RHB-104 can effectively combat MAP infections for patients with moderately to severely active Crohn’s disease.

The study drug at 600 mg was associated with significant improvements in Crohn’s Disease Activity Index scores as early as Week 2.

From baseline to 12 weeks, all participants demonstrated a significant reduction in total percentage of abnormal bowel movements, overall IBS Symptom Severity Score, abdominal pain and bloating severity, and an improvement in health-related quality of life.

Investigators observed clinical response in 15 patients (83%) who underwent the second IV reinduction. Three patients (17%) did not respond and were taken off the therapy.

In data presented during the annual ACG meeting, investigators show vedolizumab can be safe and effective for treating pediatric patients with IBD who have failed anti-TNF therapy.

In a new poster presented at the annual ACG meeting in San Antonio, researchers compare morbidity and mortality for ulcerative colitis patients with or without C. diff or CMV infections.

Ustekinumab (Stelara) has received approval from the US Food and Drug Administration for the treatment of moderate to severely active ulcerative colitis in adults.

Data from a 961-patient study shows that ustekinumab can induce and maintain remission for patients with moderate-to-severe ulcerative colitis.

Investigators discover vedolizumab induces endoscopic remission in 33% of Crohn’s disease patients and histologic remission in 66% of patients after 52 weeks.

Recent measures in the UK has led to a drop in IBD patients using corticosteroids to excess.

In a new trial, investigators test whether continuing or discontinuing ADA is more beneficial.

The largest improvements for patients taking ustekinumab occurred following treatment every 8 weeks.

The AGA-approved guidelines call for a variety of different testing to better diagnose IBS-D in adults.

The FDA-approved drug targets IBS-C patients by increasing bowel movements, while lowering abdominal pain.

In an extensive population-based study, investigators link children with IBD with an increased risk of any psychiatric disorder.

In a new multivariable regression study, investigators link depression with a lack of social support and increased IBD activity.

A further examination of data from a research clinical database shows the risk of smoking outweigh any potential benefits for UC patients.

The FDA suggests only limited use of tofacitinib to treat rheumatoid arthritis, ulcerative colitis, or psoriatic arthritis.

Investigators found positive results when examining the safety and efficacy of filgotinib in the FINCH 2 phase 3 clinical trial.

New evidence from a cumulative RCT analysis suggests irritable bowel syndrome patients do not definitively benefit from FMT treatment.